Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed through lab testing with a type of cancer called adenocarcinoma that started in the esophagus, the junction between the esophagus and stomach, or the stomach, and has either spread to other parts of the body or cannot be surgically removed.
• People whose tumor has tested negative for a protein called HER2, using standard local testing.
• People whose general health and ability to carry out daily activities falls within a certain range, rated 0 to 2 on a standard medical scale (confirm with trial site for what this means in practice).
• People whose cancer can be measured on scans using a standard set of medical criteria called RECIST v1.1.
• People who have not previously received systemic (whole-body) treatment for this cancer in its advanced or spread stage, or who received chemotherapy around the time of surgery but finished it more than 6 months ago — note: up to two prior cycles of a specific chemotherapy regimen called mFOLFOX6 may be permitted (confirm with trial site).
• People aged 18 years or older.
• People whose blood counts and organ function meet specific minimum levels, including white blood cells, red blood cells, platelets, kidney function, and liver function (confirm with trial site for exact values).
• People who are able and willing to use adequate birth control during the study, if there is any possibility of pregnancy.
• People who are able to understand what the study involves and provide written consent to participate.
• People who are willing and able to attend scheduled visits, follow the treatment plan, and complete required tests and procedures.

Who may not be able to join:

• People who are currently taking part in another clinical trial using an experimental treatment.
• People who have cancer that has spread to the brain and has not yet been treated.
• People who have moderate or severe nerve damage causing symptoms such as numbness or tingling (grade 2 or higher peripheral neuropathy).
• People who have had another active cancer within the past three years that is likely to affect treatment, require its own systemic treatment, or interfere with scan assessments.
• People being considered for the drug nivolumab who are currently taking steroid medications (such as prednisone) at a dose of 10 mg per day or more.
• People being considered for nivolumab who have a significant autoimmune disease that is currently active or required immune-suppressing treatment within the last two years.
• People being considered for nivolumab who have had an organ transplant or bone marrow transplant.
• People being considered for nivolumab who have a history of a lung condition called interstitial lung disease or pneumonitis (inflammation of the lungs).
• People with serious uncontrolled illness, such as a significant active infection, severe heart failure, unstable chest pain, or an uncontrolled heart rhythm problem.
• People who have had major surgery within the four weeks before starting the study treatment.
• People who have had an allergic reaction or sensitivity to any of the medications used in this trial.
• People with any other significant medical condition, abnormal lab result, or mental health condition that would prevent full participation in the study.

Important: Always verify eligibility with the trial site directly before applying.